Kiran Naqvi

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch et al. · The Lancet Haematology · 2020 · 325 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +9

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Michael W. Deininger, Neil P. Shah, Jessica K. Altman et al. · Journal of the National Comprehensive Cancer Network · 2020 · 264 citations · Full text

Hematological Malignancy, Chronic Myeloid Leukemia, Medicine +14

Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia

Naval Daver, Alexander E. Perl, Joseph Maly et al. · Journal of Clinical Oncology · 2022 · 179 citations · Full text

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Curtis A. Lachowiez, Sanam Loghavi, Tapan M. Kadia et al. · Blood Advances · 2020 · 153 citations · Full text

Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model

Kiran Naqvi, Guillermo Garcia‐Manero, Sagar Sardesai et al. · Journal of Clinical Oncology · 2011 · 142 citations